Marc Radin - RespireRx Pharmaceuticals Controller
| RSPIDelisted Stock | USD 0.01 0.00 0.00% |
Insider
Marc Radin is Controller of RespireRx Pharmaceuticals
| Phone | 201 444 4947 |
| Web | https://www.respirerx.com |
RespireRx Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (8.3401) % which means that it has lost $8.3401 on every $100 spent on assets. This is way below average. RespireRx Pharmaceuticals' management efficiency ratios could be used to measure how well RespireRx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.RespireRx Pharmaceuticals currently holds 2.42 M in liabilities. RespireRx Pharmaceuticals has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist RespireRx Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, RespireRx Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like RespireRx Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RespireRx to invest in growth at high rates of return. When we think about RespireRx Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| David Lovejoy | Protagenic Therapeutics | N/A | |
| Daniel Ryweck | Silo Pharma | 59 | |
| Robert MD | Protagenic Therapeutics | 74 | |
| Eric Tse | Sino Biopharmaceutical Ltd | 27 | |
| Jeffrey Bornstein | Eledon Pharmaceuticals | N/A | |
| Gregory Flesher | Eledon Pharmaceuticals | 54 | |
| Mireille MSc | Pharming Group NV | 55 | |
| Andrew Slee | Protagenic Therapeutics | 75 | |
| Anurag Relan | Pharming Group NV | 51 | |
| MBA MD | Pharming Group NV | 63 | |
| Jeroen Wakkerman | Pharming Group NV | 54 | |
| Stephen Toor | Pharming Group NV | 52 | |
| David Hovland | Eledon Pharmaceuticals | N/A | |
| Susanne Embleton | Pharming Group NV | N/A | |
| Ruud Outersterp | Pharming Group NV | 59 | |
Management Performance
| Return On Asset | -8.34 |
RespireRx Pharmaceuticals Leadership Team
Elected by the shareholders, the RespireRx Pharmaceuticals' board of directors comprises two types of representatives: RespireRx Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RespireRx. The board's role is to monitor RespireRx Pharmaceuticals' management team and ensure that shareholders' interests are well served. RespireRx Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RespireRx Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeff Margolis, VP, Treasurer, Secretary and Director | ||
| Richard Purcell, Senior Vice President - Research and Development | ||
| Arvid Carlsson, Consultant | ||
| David Dickason, VP Devel | ||
| Arnold Lippa, Executive Chairman and Chief Scientific Officer | ||
| Marc Radin, Controller |
RespireRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is RespireRx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in RespireRx Pink Sheet
If you are still planning to invest in RespireRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RespireRx Pharmaceuticals' history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |